Get the Stockscreener App
57.94
2.90%
-1.73
Ani Pharmaceuticals Inc stock is traded at $57.94, with a volume of 216.87K.
It is down -2.90% in the last 24 hours and down -0.70% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$59.67
Open:
$60.2
24h Volume:
216.87K
Relative Volume:
1.02
Market Cap:
$1.21B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
70.66
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
-1.66%
1M Performance:
-0.70%
6M Performance:
-5.56%
1Y Performance:
+0.54%
1-Day Range:
$57.39
$60.22
1-Week Range:
$57.39
$60.54
52-Week Range:
$52.50
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
57.94 | 1.21B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
ANI Pharmaceuticals (ANIP) Expected to Post Earnings on Friday - Defense World
ANI Pharmaceuticals to Present at Raymond James’ - GlobeNewswire
ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March - The Manila Times
Inside Access: ANI Pharmaceuticals Sets Stage for Dual Healthcare Conference ShowcaseKey Dates for Investors - StockTitan
ANI Pharmaceuticals (ANIP) Shares Cross Above 200 DMA - Nasdaq
Ani Pharmaceuticals Sr. VP sells $23,816 in stock By Investing.com - Investing.com Canada
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year - GlobeNewswire
ANI Pharmaceuticals, Inc. to Release Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025 - Nasdaq
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET - The Manila Times
ANI Pharmaceuticals Earnings: Rare Disease Portfolio Performance and 2025 Growth Strategy Revealed - StockTitan
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? - Yahoo Finance
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Legato Capital Management LLC Takes $334,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Buy” by Analysts - Defense World
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of "Buy" by Analysts - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group - Financial Content
abrdn plc Makes New $13.16 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals: More Than Just A Generics Company (NASDAQ:ANIP) - Seeking Alpha
ANI Pharmaceuticals (NASDAQ:ANIP) Rating Increased to Hold at StockNews.com - MarketBeat
Pacer Advisors Inc. Sells 566,516 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals Shares Strategic Insights at Conference - TipRanks
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Holdings Decreased by Pacer Advisors Inc. - Defense World
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to “Hold” at StockNews.com - Defense World
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decline in Short Interest - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
9,843 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Bought by SG Americas Securities LLC - Defense World
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now? - Nasdaq
Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 53% gain - Yahoo Finance
StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell - Defense World
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference - GlobeNewswire
ANI Pharma CEO Reveals Future Strategy: Key Insights Coming at Major Biotech Event - StockTitan
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
Clostridium Difficile Infection Treatment Market Size Worth US$ 2.28 Billion by 2034 at a CAGR Of 6.3% | Fact.MR Report - GlobeNewswire
Millennium Management LLC's Strategic Acquisition in ANI Pharmac - GuruFocus.com
ANI Maintains Course With Rare Disease Push In 2025 - News & Insights
Wedge Capital Management L L P NC Trims Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71 - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market TransformationTechnavio - Yahoo Finance
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - MSN
Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Declines By 8.5% - MarketBeat
Assenagon Asset Management S.A. Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) delivers shareholders respectable 12% CAGR over 3 years, surging 6.2% in the last week alone - Simply Wall St
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? - Yahoo Finance
ANI Pharma To Present At 43rd Annual J.P. Morgan Healthcare Conference; Webcast At 5:15 PM ET - Nasdaq
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock - MarketBeat
Ani Pharmaceuticals senior VP sells $21,568 in stock By Investing.com - Investing.com Nigeria
Ani Pharmaceuticals senior VP sells $21,568 in stock - Investing.com
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):